Lipid profile abnormalities associated with endocrine disorders

Szczepanek‐Parulska, Ewelina; Sokołowski, Jan; Dmowska, Dominika; Klimek, Jan; Stasikowski, Tomasz; Zdebski, Paweł; Olejarz, Michał; Gac, Anna; Bartecki, Michał; Ruchała, Marek

doi:10.5603/ep.a2022.0059

Cited by 5 publications

(4 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is known that in patients with acromegaly, the inhibition of the activity of lipoprotein lipase and lecithin–cholesterol acyltransferase under the influence of GH and insulin resistance results in an increase in triglycerides and a decrease in the HDL fraction [ 39 ]. IGF-1 enhances the uptake of free fatty acids by adipose tissue and the liver and induces lipogenesis.…”

Section: Discussionmentioning

confidence: 99%

“…This is due to the high concentration of GH and the dysfunction of the visceral adipose tissue, which leads to insulin resistance and impaired glucose tolerance. Treatment of acromegaly leads to an increase in body fat and a decrease in lean body mass within a few months of GH normalization [37,38] It is known that in patients with acromegaly, the inhibition of the activity of lipoprotein lipase and lecithin-cholesterol acyltransferase under the influence of GH and insulin resistance results in an increase in triglycerides and a decrease in the HDL fraction [39]. IGF-1 enhances the uptake of free fatty acids by adipose tissue and the liver and induces lipogenesis.…”

Section: Fto Polymorphisms and Their Influence On Lipids Metabolismmentioning

confidence: 99%

See 1 more Smart Citation

FTO Gene Polymorphisms and Their Roles in Acromegaly

Jawiarczyk-Przybyłowska

Kuliczkowska-Płaksej

Kolačkov

et al. 2023

IJMS

View full text Add to dashboard Cite

The major causes of both morbidity and mortality in patients with acromegaly are cardiovascular diseases (CVDs). The polymorphisms of the fat mass and obesity-associated gene (FTO) are associated with obesity, as well as with an increased risk of CVDs. The aim of the study was to determine the relationship of risk alleles of four FTO gene polymorphisms with selected parameters of lipid and glucose metabolism as well as with IGF-1 and GH levels in the group of patients with acromegaly compared to the control group. The study group consisted of 104 patients with acromegaly and 64 healthy subjects constituting the control group. In the whole acromegaly group, the data reveal that the homozygous for risk allele carriers (rs1421085, rs9930506, rs9939609) as well as carriers of only one risk allele have lower IGF-1 concentrations. In the well-controlled acromegaly group, the homozygous for three risk allele carriers of FTO gene polymorphisms have lower HDL cholesterol concentration (rs1121980, rs1421085, rs993609). In the cured acromegaly group, homozygous risk allele carriers rs9930506 tend to have higher levels of total cholesterol and LDL cholesterol. These associations are not observed in the control group. Conclusion: there is an association between FTO gene polymorphisms and the metabolism of lipids, suggesting that the FTO gene may be associated with higher CVD risk in patients with acromegaly. In addition, there is an association between FTO gene polymorphisms and IGF-1, implying that FTO gene may influence/modify IGF-1 synthesis. Further investigation on a larger scale is required to provide more precise evidence.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Fto Polymorphisms and Their Influence On Lipids Metabolismmentioning

confidence: 99%

FTO Gene Polymorphisms and Their Roles in Acromegaly

Jawiarczyk-Przybyłowska

Kuliczkowska-Płaksej

Kolačkov

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Data on dyslipidaemia in CS is limited. Usually raised triglycerides, total and LDL cholesterol, and reduced HDL cholesterol are observed ( 8 , 37 ). However, abnormal lipid panel might result from obesity alone ( 38 ).…”

Section: Discussionmentioning

confidence: 99%

Cushing’s syndrome is associated with altered adipokine profile

et al. 2022

Self Cite

View full text Add to dashboard Cite

IntroductionAdipokines are signaling molecules involved in the integration of metabolism. Changes in their concentrations were observed in obesity, metabolic syndrome, diabetes mellitus and cardiovascular diseases, as well as endocrine disorders. Cushing’s syndrome is associated with metabolic dysregulation, but the significance of adipokines in this entity and related complications is largely unknown. The aim of our study was to determine the concentrations of adipokines: fetuin A, fatty acid binding protein 4 (FABP4) and retinol binding protein 4 (RBP4) in Cushing’s syndrome and to assess their relation to established cardiovascular and diabetes risk markers.MethodsWe examined 21 subjects with Cushing’s syndrome and 24 healthy controls in a cross-sectional manner. Venous blood samples were analysed for adipokines, cortisol, adrenocorticotrophin, glucose, insulin, glycated haemoglobin (HbA1c), triglycerides, cholesterol fractions, thyrotropin and free thyroid hormones concentrations. Patients’ body mass index (BMI) was evaluated, homeostatic model assessment-insulin resistance and Systematic Coronary Risk Evaluation (SCORE) were calculated.ResultsWe found that the concentration of fetuin A was lower, while FABP4 and RBP4 concentrations were higher in Cushing’s syndrome compared to controls [156.4 ± 60.0 µg/ml vs 260.7 ± 49.6 µg/ml; 79.8 (35.2-156.1) ng/ml vs 27.9 (17.1-36.7) ng/ml and 34 (30-37.7) mg/l vs 25.8 (23.6-27.7) mg/l, respectively]. Fetuin A correlated inversely, while FABP4 and RBP4 positively, with the concentrations of urinary free cortisol and adrenocorticotrophin. Fetuin A was positively related to LDL-cholesterol, and negatively to SCORE and HbA1c. FABP4 was associated positively with BMI, HbA1c and triglycerides, while RBP4 correlated positively with triglycerides and systolic blood pressure.ConclusionsAdipokines’ concentrations change in hypercortisolism. Further research is needed to ascertain whether adipokines are involved in the development of metabolic complications accompanying Cushing’s syndrome or secondarily reflect metabolic dysregulation.

show abstract

“…Lipid profile alterations associated with endocrine disorders are generally unfavorable and proatherogenic. Even though in some conditions, e.g., overt hyperthyroidism, a decrease in deleterious lipoproteins like low-density lipoprotein cholesterol (LDL-C) is seen, it cannot be viewed as unequivocally positive since the disease itself is associated with an increased cardiovascular risk ( 5 ). The problem of dyslipoproteinemia in endocrinological conditions is immense and would require a very long review.…”

Section: Introductionmentioning

confidence: 99%

Lipoprotein alterations in endocrine disorders - a review of the recent developments in the field

Olejarz,

Szczepanek-Parulska,

Ruchala

2024

Front. Endocrinol.

Self Cite

View full text Add to dashboard Cite

Dyslipidemia is one of the most common disorders worldwide, which, if left untreated, results in a multitude of complications. Thus proper diagnostics, which includes identifying of secondary causes of dyslipidemia is crucial. Endocrine disorders are an important cause of secondary dyslipidemia. This paper aims to review the publications on lipoprotein alterations in endocrine disorders from the past two years and provide an overview of the recent discoveries in this dynamically developing and large field. Significant changes in lipoprotein serum concentrations are present in most endocrinological diseases and can be modified with proper treatment. Some lipoproteins have also been proposed as markers in some endocrine diseases, e.g., thyroid carcinoma. From the scope of endocrine disorders, the largest number of studies explored the lipoprotein changes in polycystic ovary syndrome and in women during the menopausal and peri-menopausal period. Even though the association of thyroid disorders with dyslipidemia is already well studied, new research has delivered some exciting findings about lipoprotein alterations in euthyroid patients with either positive antithyroid peroxidase antibodies or reduced sensitivity to thyroid hormones. The problem of the adverse metabolic profile, including dyslipidemia in hypoprolactinemia has been recognized. Moreover, this review describes other significant discoveries encompassing lipoprotein alterations in disorders of the adrenals, thyroid, parathyroid glands, pituitary, and gonads. The up-to-date knowledge of the influence of endocrine disorders and hormonal changes on serum lipoproteins is prudent as it can significantly impact therapeutic decisions.

show abstract

Lipid profile abnormalities associated with endocrine disorders

Cited by 5 publications

References 82 publications

FTO Gene Polymorphisms and Their Roles in Acromegaly

FTO Gene Polymorphisms and Their Roles in Acromegaly

Cushing’s syndrome is associated with altered adipokine profile

Lipoprotein alterations in endocrine disorders - a review of the recent developments in the field

Contact Info

Product

Resources

About